As companies move from concept to early development, the first real regulatory decisions are often made almost implicitly, during study design, data planning, or discussions about “what we need to get started.”
At that point, regulatory strategy is not always formalised yet, but it is already taking shape.
These early choices matter. They define how your data will be interpreted later, how flexible your development path remains, and how aligned you are with future expectations from health authorities or notified bodies.
We see this consistently across pharmaceuticals (small molecules and biologics) as well as medical devices and IVDR: once development accelerates, it becomes harder to adjust direction without impacting timelines or rework.
The challenge is rarely access to guidance. It is translating that guidance into a coherent and practical strategy that fits the realities of early development.
At Starodub, we support teams at this stage by helping structure early regulatory thinking, before decisions become constraints rather than choices.
If you are currently shaping or reviewing your early development strategy, we are happy to provide a second perspective and think along with you. Feel free to contact us via [email protected].
